Lilly JDCG
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Tabalumab in Combination with Bortezomib and Dexamethasone in Patients with Previously Treated Multiple Myeloma.
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Tabalumab in Combination with Bortezomib and Dexamethasone in Patients with Previously Treated Multiple Myeloma.